EOFlow faces a patent infringement lawsuit from fellow insulin patch pump maker Insulet as it attempts to bring in millions in a new funding round. The Korea-based company develops the EOPatch — a tubeless, wearable and fully disposable insulin delivery device. EOFlow was at one point set to be acquired by Medtronic for $738 million last […]
Legal News
Report: Court says SiBio can’t sell CGM in some European countries amid Abbott IP battle
JUVE-Patent reports that The Hague recently handed down two new decisions in a CGM patent battle between Abbott and SiBio. One case saw an Abbott patent infringement application shot down, while the other granted the U.S. medtech giant’s claim. The granted one could mean SiBio can’t distribute its CGMs in Germany, France, the Netherlands and […]
Dexcom, Abbott ask for another trial in CGM patent spat
Abbott (NYSE:ABT) and Dexcom (Nasdaq:DXCM) both submitted legal briefs angling for another trial in an ongoing continuous glucose monitor (CGM) patent spat. In March, the U.S. District Court for the District of Delaware found that Dexcom violated a single patent belonging to Abbott and its FreeStyle Libre sensors. However, the court found that Dexcom did […]
Report: Abbott files trio of patent lawsuits over CGM tech in Europe
Abbott (NYSE:ABT) filed three patent lawsuits against SiBionics and its distribution partner in Europe, JUVE-Patent reports. The lawsuits include patent infringement allegations centered around continuous glucose monitoring (CGM) devices, according to the report. Abbott filed them against China-based SiBionics and its sales partner Umedwings at the Unified Patent Court. SiBionics develops, manufactures and distributes CGM […]
Report: Insulet trumps Medtrum again in French patent spat
JUVE-Patent reports that the Judicial Court of Paris again ruled in favor of Insulet (Nasdaq:PODD) in its patent battle with Medtrum. According to the report, the court sided with Insulet in a case regarding the company’s patent (EP 1 874 390). The ruling finds that Medtrum’s A6 and A7+ TouchCare insulin pump devices infringe the valid […]
BD inks $85M settlement over Alaris defect disclosure claims
BD (NYSE:BDX) announced that it filed settlement documents for an $85 million agreement to resolve claims regarding its Alaris infusion pump technology. The Alaris system has been much maligned over the past few years. Its troubles date back to a Class I recall in early 2020. The recall, which centered around multiple system errors, software […]
Report: There’s still ‘mutual interest’ with EOFlow, Medtronic despite deal falling through
Business Korea reports that EOFlow CEO Kim Jae-jin is leaving the door open with regard to the company’s collapsed deal with Medtronic (NYSE:MDT). Medtronic announced this week that it terminated its $738 million agreement to acquire EOFlow, a maker of insulin patch pumps. The medtech giant cited “multiple breaches” of terms in the agreement as […]
Lawsuit alleges ‘potentially problematic’ patient data sharing from Medtronic Diabetes devices
A class-action lawsuit filed against Medtronic (NYSE:MDT) alleges that the company’s insulin delivery devices shared patient data with third parties. The lawsuit — filed by the plaintiff “A.H.” in U.S. District Court in Central California — levels allegations against Medtronic and its MiniMed and InPen devices. It addresses MiniMed’s transmission and disclosure of personally identifiable information […]
Report: Insulet prevails over Medtrum in France patent spat
According to a report in Europe, a Paris court found that Medtrum’s latest insulin pumps infringe an Insulet (Nasdaq:PODD) patent. JUVE Patent reported that earlier this month, the Judicial Court of Paris declared the infringement. The court found that Medtrum’s newest pump base and patch reservoir models violate the EP2438957B1 patent from Insulet. In declaring […]
Boston Scientific hit with $42M verdict in drug-eluting stents IP case
Boston Scientific (NYSE:BSX) must pay $42 million in unpaid royalties to TissueGen and the University of Texas, a federal jury in Delaware has ruled. The jury verdict yesterday came after the finding that Boston Scientific’s Synergy BP drug-eluting stents infringed on TissueGen and the university’s IP. The patent under question arose out of research that […]
